Company: APM
Filing Date: 2025-11-17
Form Type: F-1
Source: 0001213900-25-111548
Chunk: 20

Company: Aptorum Group Ltd
Filing Date: 2025-11-17
Form: F-1
Chunk 20
---
the “Placement Agent Warrants”) to purchase up to 60,000 Class A Ordinary Shares, at an exercise price equal to $2.50 per share. The Placement Agent Warrant are exercisable immediately upon issuance on October 1, 2025 and expire on the earlier of 24 months from the effective date of this registration statement or October 10, 2030 After deducting fees due to the Placement Agent and our estimated offering expenses, we expect the net proceeds from the October 2025 Offering to be approximately $1.725 million. Registered Direct Offering On January 2, 2025, the Company entered into a certain securities purchase agreement (the “Securities Purchase Agreement”) with certain non-affiliated institutional investors pursuant to which the Company sold 1,535,000 Class A Ordinary Shares of the Company, par value $0.00001 per share at a per share price of $2.00 for gross proceeds of $3,070,000 in a registered direct offering under the Company’s existing shelf registration statement on Form F-3 (File No. 333-268873). 4 Merger Transaction In the second quarter of fiscal 2025, the Company determined that it would be in its and its shareholders best interest to merge with DiamiR On June 2, 2025, we entered into the Letter of Intent with DiamiR for the acquisition of 100% of the outstanding shares of DiamiR for consideration in shares. Pursuant to the Letter of Intent, we entered into the Merger Agreement on July 14, 2025, where the Company will acquire 100% of DiamiR outstanding shares of common stock with consideration to be paid in shares at the closing (the “DiamiR Closing”). Upon consummation of DiamiR Merger, DiamiR will become a wholly-owned subsidiary of the Company, and the existing DiamiR stockholders and existing Company shareholders will own approximately 70% and 30%, respectively, of the outstanding shares of the combined company. Pursuant to the Letter of Intent, the Company entered into a licensing agreement and management agreement with DiamiR concurrently with the Merger Agreement. The closing of the DiamiR Merger will be subject to customary closing conditions, including the preparation and receipt of certain audited financials and obtaining shareholder approval of the DiamiR Merger. Therefore, there is no guarantee that such a transaction will occur. DiamiR is a molecular diagnostic company focused on developing minimally